Highlights
The Phase II trial evaluating the combination of the multi-kinase inhibitor cabozantinib and the PD-1 inhibitor nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) demonstrated a high rate of stable disease (90%) but a very low objective response rate (5%).
Due to the failure to reach the predefined response threshold in the first stage of the Simon’s two-stage design, enrollment was terminated early.
